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Efficacy of MEK inhibition in a K-Ras-driven
cholangiocarcinoma preclinical model
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Li Che2,3, Antonio Cigliano6, Silvia Ribback6, Frank Dombrowski6, Antonio Cossu8, John Gordan9, Diego F. Calvisi6,
Matthias Evert5, Yan Liu1 and Xin Chen2,3,4
Abstract
Intrahepatic cholangiocarcinoma (iCCA) is a deadly malignancy with limited treatment options. Gain-of-function
mutations in K-Ras is a very frequent alteration, occurring in ~15 to 25% of human iCCA patients. Here, we established
a new iCCA model by expressing activated forms of Notch1 (NICD) and K-Ras (K-RasV12D) in the mouse liver (K-Ras/
NICD mice). Furthermore, we investigated the therapeutic potential of MEK inhibitors in vitro and in vivo using human
CCA cell lines and K-Ras/NICD mice, respectively. Treatment with U0126, PD901, and Selumetinib MEK inhibitors
triggered growth restraint in all CCA cell lines tested, with the most pronounced growth suppressive effects being
observed in K-Ras mutant cells. Growth inhibition was due to reduction in proliferation and massive apoptosis.
Furthermore, treatment of K-Ras/NICD tumor-bearing mice with PD901 resulted in stable disease. At the molecular
level, PD901 efficiently inhibited ERK activation in K-Ras/NICD tumor cells, mainly leading to increased apoptosis.
Altogether, our study demonstrates that K-Ras/NICD mice represent a novel and useful preclinical model to study K-
Ras-driven iCCA development and the effectiveness of MEK inhibitors in counteracting this process. Our data support
the usefulness of MEK inhibitors for the treatment of human iCCA.
Introduction
Cholangiocarcinoma (CCA) is a type of malignancy with
tumor cells arising within the liver or bile ducts with
features of cholangiocyte differentiation1,2. In recent
years, the incidence rate of CCA has been raising in the
Western world3,4. Anatomically, CCA can be classified as
intrahepatic (iCCA), perihilar (pCCA), and distal cho-
langiocarcinoma (dCCA). Hepatocellular carcinoma
(HCC) and iCCA are the most common primary liver
cancer, accounting for over 95% of all cases of primary
liver cancer reported annually. iCCA is a deadly malig-
nancy with limited treatment options. Surgical resection
and liver transplantation are the only curative treatment
approaches, but they can only be applied for early stage
iCCA patients1. Unfortunately, most of iCCA cases are
diagnosed at advanced stage, when curative treatments
are not feasible. The combination of gemcitabine and
cisplatin is the standard of care treatment for iCCA
patients5. However, this therapeutic strategy has limited
efficacy, with a median overall survival limited to
11.7 months5. As FDA-approved targeted therapies for
iCCA are lacking, iCCA remains a deadly malignancy with
a 5-year survival rate lower than 10%6.
Gain-of-function mutations of the K-Ras gene represent
one of the most frequent alterations in iCCA. Indeed,
multiple studies indicate that K-Ras mutations could be
found in ~15–25% of human iCCAs7–10. Activated K-Ras
mutations lead to constitutive hyper-activation of the Raf-
MEK-ERK cascade (also known as the mitogen-activated
protein kinase pathway or MAPK), an evolutionary con-
served signaling pathway driving cell proliferation and
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survival. Targeting the oncogenic forms of K-Ras has been
proven to be highly problematical. This depends on the
fact that the K-Ras protein does not contain pockets or
active sites that can be exploited for binding drugs. In
addition, GTP and GDP bind extremely tightly to K-Ras,
making it arduous to identify or design drugs that are
effective competitive inhibitors11. Much effort has con-
sequently been devoted to inhibit its downstream effec-
tors, including Raf and MEK1/2 proteins11. In particular,
MEK1/2 inhibitors have been extensively investigated
in vitro, in preclinical models, and tested in clinical
trials12,13. For instance, the MEK1/2 inhibitor Trametinib
has been approved by the FDA for the treatment of B-Raf
mutant metastatic and unresectable melanoma14. Despite
the advances in the development of MEK inhibitors for
cancer treatment, whether these drugs are useful for the
treatment of iCCA, especially those with K-Ras-activating
mutations, has been assessed only marginally, both
in vitro and in vivo.
Here, we sought to determine the therapeutic potential
of MEK inhibitors in a panel of human iCCA cell lines as
well as in a novel mouse iCCA preclinical model char-
acterized by the concomitant activation of K-RasG12D
mutant allele and overexpression of an activated/cleaved
form of Notch1 (NICD) (K-Ras/NICD). Our study sug-
gests the efficacy of MEK inhibitors against K-Ras mutant
iCCAs, supporting the further development of drugs
targeting MEK1/2 for the treatment of K-Ras mutant
iCCA.
Results
K-Ras mutant human CCA cell lines are highly sensitive to
MEK inhibitors
As a first step to evaluate the therapeutic potential of
MEK inhibitors for the treatment of iCCA, we collected
seven human CCA cell lines. We sequenced the cell lines
for K-Ras mutations and found that KKU213, HuCCT1,
and RBE harbor activated K-Ras mutations, whereas the
remaining four CCA cell lines, including KMCH, Huh28,
MzCHa1, and OCUG, display wild-type K-Ras alleles
(Supplemental Table 1). As surrogate marker of MAPK
pathway activation, we assessed the levels of phosphory-
lated/activated (p)-ERK1/2 proteins in the seven cell lines.
We found that p-ERK1/2 was expressed in all CCA cell
lines irrespective of K-Ras mutation status (Supplemental
Figure 1). Subsequently, we treated the seven cell lines
with the MEK inhibitor U0126. U0126 is the most widely
used and highly selective MEK1/2 inhibitor for in vitro
studies15. We found that U0126 efficiently inhibits the
growth of all CCA cell lines with IC50 ranging from ~20 to
100 μM (Supplemental Table 1). Of note, K-Ras mutant
CCA cell lines resulted to be more sensitive than K-Ras
wild-type CCA cells to U0126 administration (Supple-
mental Table 1).
Subsequently, we performed detailed analysis of MEK
inhibitors on the growth of CCA cells by determining the
proliferation and apoptosis rates in four selected CCA cell
lines. For this purpose, we selected two K-Ras mutant
(HuCCT1 and KKU213) and two K-Ras wild-type
(KMCH and Huh28) CCA cell lines that were treated
with U0126. Administration of U0126 induced a slight
decrease in proliferation and a prominent increase in
apoptosis in the four CCA cell lines tested (Fig. 1 and
Supplemental Figure 2). Once again, the highest growth
restraint was detected in K-Ras mutant cell lines (Fig. 1
and Supplemental Fig. 2).
At the biochemical level, U0126 efficiently inhibited p-
ERK1/2 expression and its downstream target p-eIF4E
(Fig. 2a). A feedback activation of AKT cascade, as indi-
cated by phosphorylated/activated levels (p-) of AKT
(S473), AKT(T308), and PRAS40, was noted in both
K-Ras mutant and wild-type CCA tumor cells, especially
at the early time points (Fig. 2a). However, no consistent
upregulation of mTOR signaling, as revealed by phos-
phorylated/activated (p)-mTOR, (p)-RPS6, and (p)-4EBP1
expression was detected, suggesting that elevated levels of
the AKT cascade do not always lead to upregulation of
mTOR signaling in U0126-treated human CCA cell lines.
As concerns proliferation proteins, levels of Cyclin A and
Cyclin B1 were consistently downregulated in U0126-
treated cells (Fig. 2b). Regarding apoptosis and autophagy
pathways, expression of cleaved caspase-3 was increased,
indicating that U0126 promotes apoptosis in human CCA
cells. Furthermore, we found the consistent down-
regulation of pro-survival protein Survivin by U0126 in all
CCA cells tested (Fig. 2c). The levels of other apoptosis-
related proteins, including Mcl-1, Bim, BCL-XL, and
BCL-2, did not change consistently (Fig. 2c).
While U0126 is widely used in vitro to study the efficacy
of MEK inhibitor for cancer treatment, it is not suitable for
in vivo experiments. PD0325901 (PD901) was developed to
achieve high membrane permeability and high systematic
exposure in vivo16 and it has been widely used for pre-
clinical and clinical studies12,13. We therefore treated the
four CCA cell lines with PD901 and investigated whether
PD901 also regulates cell proliferation and apoptosis in
human CCA cells. Indeed, similar to what we observed for
U0126, a minor decline in proliferation and massive
apoptosis was detected in all PD901-treated cell lines in a
dose-dependent manner, especially in K-Ras mutant cells,
when compared with solvent-treated and untreated cells
(Fig. 1 and Supplemental Figure 2). In addition, we eval-
uated the effect of Selumetinib, a MEK inhibitor widely
used in clinical trials (https://clinicaltrials.gov) on the same
cell lines (Supplemental Figure 3). Once again, the highest
growth restraint was achieved in K-Ras CCA mutant cells,
although significant growth inhibition was also detected in
K-Ras wild-type cells (Supplemental Figure 3). Equivalent
Dong et al. Cell Death and Disease  (2018) 9:31 Page 2 of 13
Official journal of the Cell Death Differentiation Association
results were also obtained, in a dose-dependent manner,
when subjecting the four CCA cell lines to treatment with
the ERK1/2 inhibitor SCH772984 (Supplemental Figure 4).
In summary, our in vitro data suggest that MEK (and
ERK) inhibitors may be effective against human CCA
cells, especially those with K-Ras mutations.
Activated Notch1 synergizes with K-RasG12D to promote
intrahepatic cholangiocarcinoma development in mice
Next, to evaluate the importance of MEK inhibitors on
iCCA growth in vivo, we developed a mouse model har-
boring a mutant, oncogenic form of K-Ras gene in the liver.
Specifically, we hydrodynamically injected Cre recombinase
into LSL-K-RasG12D mice (n= 5). Briefly, LSL-K-RasG12D
mice carry a Lox-Stop-Lox (LSL) sequence followed by the
K-RasG12D point mutation allele17. In these mice, Cre
recombinase deletes the LSL cassette and allows the
expression of mutant K-Ras, which is locked in a con-
stitutively active, oncogenic conformation17. We found that
over long term, no liver tumors developed in LSL-K-RasG12D
mice (data not shown). Histological examination showed
that the hepatic parenchyma of Cre-injected LSL-K-RasG12D
mice was completely normal (not shown), suggesting that
activation of K-Ras alone is unable to trigger carcinogenesis
in the mouse liver. The results are equivalent to those
obtained following the hydrodynamic injection of the pT3-
EF1a-K-RasG12D construct in mice18. Activated Notch sig-
naling is widely implicated in human CCA development
and progression19,20. Previous data from our group indicate
that overexpression of NICD (the intracellular domain of
Fig. 1 Effect of the MEK inhibitors U0126 and PD901 on the cell proliferation and apoptosis of K-Ras mutant HuCCT1 and KKU213 human
CCA cell lines. a, b Cell proliferation and apoptosis rates of HuCCT1 cells treated with U0126 (a) or PD901 (b). c, d Cell proliferation and apoptosis rates
of KKU213 cells treated with U0126 (c) or PD901 (d). Tukey Kramer test, p < 0.05, a vs. untreated cells; b vs. DMSO-treated cells; c vs. PD901 0.1 µM
Dong et al. Cell Death and Disease  (2018) 9:31 Page 3 of 13
Official journal of the Cell Death Differentiation Association
Notch1) alone leads to iCCA formation over long time in
mice21. Thus, we hypothesized that activated Notch1 may
synergize with K-RasG12D mutant to promote iCCA for-
mation. To substantiate this hypothesis, we hydro-
dynamically co-injected Cre with NICD into the liver of
LSL-K-RasG12D mice (Fig. 3a), thus allowing co-expression
of NICD with K-RasG12D mutant (K-Ras/NICD; n= 10). Of
note, liver tumors developed as early as 8 weeks post
injection in K-Ras/NICD mice (Fig. 3b). By ~14–16 weeks
post injection, all mice (n= 5) developed high tumor bur-
den and were required to be killed (Fig. 3b).
Histologically, all liver tumors exhibited a glandular
phenotype, indicating that the combined oncogenic effect
of K-Ras/NICD signaling results in the exclusive
development of iCCA, but not HCC or HCC/iCCA mixed
tumors, in mice (Fig. 3b). Some of the tumors consisted of
small ductular structures with variable amount of des-
moplastic stroma, while others exhibited a prominent
cystic morphology (Fig. 3b). Some tumors showed both
phenotypes intermingling with each other. Cellular atypia
was low in cystic lesions, while the other tumors showed
moderate and sometimes severe cytologic atypia, including
an increase of mitotic figures and apoptotic bodies. An
additional sign of malignancy was the invasion and
destruction of the surrounding hepatocellular parenchyma.
At the molecular level, all K-Ras/NICD tumor cells were
positive for the biliary epithelial cell marker CK19, con-
firming that tumors were indeed iCCA (Fig. 4a). In
Fig. 2 Biochemical analysis of U0126-treated human CCA cell lines. K-Rasmutant HuCCT1 and KKU213 cells as well as K-Ras wild-type KMCH cells
were treated with U0126 at IC50 concentration, and analyzed at 0, 2, 6, and 24 h post treatment for a Ras/MAPK and AKT/mTOR pathways; b cell
proliferation proteins; and c cell apoptosis-related proteins
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addition, ectopically expressed NICD was visualized by
Myc-tag immunostaining (Fig. 4a), while activation of K-
RasG12D mutant was validated by elevated levels of one of
its major downstream effector, namely p-ERK1/2 (Fig. 4a).
K-Ras/NICD iCCA cells were highly proliferative as
indicated by an increase in mitotic figures and Ki67-
positive nuclear staining (Fig. 4a). Human iCCA is well
known to exhibit an extensive desmoplasia22. Accord-
ingly, K-Ras/NICD tumors displayed a high desmoplastic
reaction, as revealed by histologic analysis and highlighted
by immunoreactivity for vimentin (VIM) in the stromal
fibroblasts and myofibroblasts as well as strong Sirius Red
staining of the collagen fibers within the tumor tissue
(Fig. 4a). At the biochemical level, the AKT/mTOR
pathway, a major signaling cascade promoting cell survi-
val, was found to be activated in late-stage K-Ras/NICD
tumors (Fig. 4b). Cell proliferation-related proteins,
including PCNA, Cyclin B1, Cyclin D1, and Cyclin E, were
also highly expressed in K-Ras/NICD iCCA. Similarly,
Survivin, an important anti-apoptosis protein, was upre-
gulated in these tumors (Fig. 4c).
In summary, our study demonstrates that activated
Notch1 synergizes with K-RasG12D mutant to promote
development of cholangiocellular tumors in mice that
closely resemble human iCCA. Thus, K-Ras/NICD mice
represent a novel murine model to study K-Ras-driven
iCCA development in vivo.
Treatment with the MEK inhibitor PD901 leads to stable
disease in K-Ras/NICD mice
Having established a K-Ras-driven iCCA model, we
next investigated the potential therapeutic activity of
MEK inhibitors in this iCCA preclinical model. For this
purpose, we hydrodynamically transfected Cre and NICD
into LSL-K-RasG12D mice. At 11.7 weeks post injection,
when K-Ras/NICD mice display low to moderate iCCA
tumor burden, a cohort of mice (n= 6) was harvested as
pre-treatment baseline measurement. In the meantime,
we started to treat K-Ras/NICD mice with either vehicle
(n= 9) or the MEK inhibitor PD901 (n= 8). PD901 was
selected for the in vivo treatment as it has been already
evaluated in experimental models23–25 and is currently
investigated in clinical trials of multiple tumor types
(Clinical trial number: NCT02510001, NCT02022982,
and NCT02039336). All mice were killed at 14.3 weeks
post injection (Fig. 5a). We used total liver weight as the
measurement of iCCA tumor burden in mice26. Of note,
PD901-treated mice displayed a significantly lower total
liver weight than vehicle-treated mice (Fig. 5b, 5c). In
addition, PD901-treated mice had a similar tumor burden
Fig. 3 Activated Notch1 (NICD) synergizes with K-RasG12D to promote iCCA development in mice. a Study design. b Gross images and H&E
staining of K-Ras/NICD mouse liver at various time points. W: weeks post injection. Scale bars: 500 μm in x40, 200 μm in x100
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to that of the pretreated mouse cohort (Fig. 5d), sug-
gesting that PD901 led to stable disease in K-Ras/NICD
mice.
Histologically, we found that K-Ras/NICD tumors in
pretreated, vehicle-treated, and PD901-treated mice were
highly similar. Indeed, treatment with PD901 did not alter
the histomorphologic features of the lesions and all tumors
were still either cystic, ductular, or combined iCCA
(Fig. 5b). Also, all K-Ras/NICD tumor cells were CK19
positive (Fig. 6a) and expressed ectopically injected Myc-
tagged NICD following PD901 administration (Fig. 6a). As
another measurement of tumor burden, we quantified the
CK19(+) area in pretreated, vehicle-treated, and PD901-
treated mouse liver samples. We found that the CK19(+)
area was larger in vehicle-treated liver samples than that in
pretreated ones. PD901 significantly decreased CK19(+)
area when it was compared with vehicle-treated liver tissues;
and PD901-treated and pre-treatment liver specimens
showed a similar CK19(+) area (Fig. 6b). In line with the
decrease in tumor burden in PD901-treated animals when
compared to vehicle-treated ones, we found histopathologic
signs of tumor regression, such as accumulation of apop-
totic bodies and fibrinoid or hemorrhagic necrosis, often
accompanied by an inflammatory reaction in some of the
tumors (Fig. 7d). Subsequently, proliferation and apoptosis
rates were determined in iCCA lesions. Of note, PD901
treatment did not significantly decreased iCCA cell pro-
liferation but, in contrast, strongly induced tumor cell
apoptosis (Fig. 6c). The increased apoptosis was confirmed
by the conspicuous accumulation of apoptotic cells that was
already noticed in conventional histopathology (Fig. 7d).
Next, we investigated the signaling pathways that might
be regulated by PD901 in K-Ras/NICD iCCA lesions. We
found that tumor burden was higher in vehicle-treated
than in PD901-treated tumor samples (Figs. 5c and 6b).
Thus, to exclude that the observed differences were due to
the different tumor burden, we compared PD901-treated
K-Ras/NICD liver lysates with pretreated K-Ras/NICD
counterparts (i.e., K-Ras/NICD iCCA at 11.7 weeks post
injection) that display an equivalent liver load by iCCA
lesions (Figs. 5d and 6b). As expected, western blotting
demonstrated similar Myc-tag levels (indicating the
hydrodynamically injected NICD) in the pre-treatment and
PD901-treated livers (Fig. 7b). As a biomarker of PD901
efficacy, we found that p-ERK1/2 expression was com-
pletely abolished in PD901-treated K-Ras/NICD livers
(Fig. 7a). No further activation of AKT was observed after
treatment with PD901 in mice (Fig. 7b). The expression of
Fig. 4 Molecular and biochemical features of K-Ras/NICD cholangiocellular tumors. a Immunohistochemical staining of K-Ras/NICD tumors at
8 weeks (8 W) and 16 weeks (16 W) post-hydrodynamic injection. b Western blotting of AKT/mTOR pathway genes in wild-type normal liver (WT) and
K-Ras/NICD tumors at 8 W and 16W post-hydrodynamic injection. c Western blotting of cell proliferation and apoptosis-related genes in WT normal
liver and K-Ras/NICD tumors at 8 W and 16W post-hydrodynamic injection
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proteins involved in cell proliferation, including PCNA,
Cyclin A, Cyclin B1, Cyclin D1, and Cyclin E, was not
altered (Fig. 7c). As concerns apoptosis-related proteins, a
mild but consistent increased expression of cleaved
caspase-3 and -7 was detected in PD901-treated livers
(Fig. 7d). Expression of Mcl-1, Bim, BCL-XL, and BCL-2
did not differ between control and PD901-treated livers
(Fig. 7d). However, a consistent downregulation of Survivin
expression in PD901-treated tumors was observed
(Fig. 7d).
In summary, our study indicates that targeting MEK
proteins in K-Ras/NICD mice leads to stable disease
mainly due to the induction of iCCA cell apoptosis.
Frequent activation of the MAPK pathway in human
cholangiocarcinoma
Finally, to stratify the iCCA patients who might benefit
from the use of MEK inhibitors, we assessed the
mutations frequency in K-Ras as well as the activation of
the MAPK signaling in a collection of human iCCA spe-
cimens. Mutations in K-Ras were detected in 20 of 98
(20.4%) samples. All specimens harboring mutations in
K-Ras displayed activation of the Ras/MAPK signaling, as
assessed by immunohistochemistry for p-ERK1/2 proteins
(Fig. 8a). Of note, activation of the Ras/MAPK pathway by
immunohistochemistry was detected in additional 53
iCCA samples with wild-type K-Ras from the same col-
lection (Fig. 8b), indicating the almost ubiquitous induc-
tion of this signaling cascade in human iCCA.
Discussion
Preclinical murine models are critical to study the
oncogenic potential of a given gene as well as for testing
the therapeutic potential of novel therapies for cancer
treatment. Because of the high prevalence of K-Ras
mutations in human iCCA, several mouse models with
Fig. 5 Treatment with the MEK inhibitor PD901 leads to stable disease in K-Ras/NICD mice. a Study design. b Gross images and H&E staining
of K-Ras/NICD mouse liver at 11.7 weeks post injection (pre-treatment); vehicle treated at 14.3 weeks post injection as well as PD901 treated at
14.3 weeks post injection. Scale bars: 500 μm; c Liver weight comparison in vehicle and PD901-treated K-Ras/NICD mice; d Liver weight comparison
in pretreated and PD901-treated K-Ras/NICD mice. Pre Pre-treatment, Veh Vehicle
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activating K-Ras mutations have been developed. For
instance, it has been reported that K-RasG12D synergizes
with loss of p53 to promote iCCA formation by ~18 weeks
of age in mice27. However, in this model, HCC or mixed
HCC/iCCA could also develop27. In another model, using
inducible Cre recombinase, Marsh et al. showed that
AhCreER2T+;Ptenf/f;K-RasG12D mice developed iCCA
~43 days after Cre induction by β-naphthoflavone
administration28. Although these studies support a pivo-
tal role of K-Ras mutation in cholangiocarcinogenesis,
none of these animal models has been used to characterize
the therapeutic potential of drugs for iCCA treatment. In
our current study, we reported the establishment of a
novel murine iCCA model induced by activated K-Ras and
Notch1 alleles. Consistent with previous studies27,28, acti-
vation of K-Ras alone in the mouse liver did not lead to any
abnormality. Overexpression of NICD alone only induces
iCCA formation after a long latency29. In contrast, con-
comitant activation of K-Ras and Notch1 significantly
decreased the latency of tumor development, leading to
iCCA formation by ~11 weeks post-hydrodynamic trans-
fection. At the biochemical level, we demonstrated that
K-Ras/NICD iCCAs display elevated levels of p-ERK1/2, a
major signaling event downstream of the K-Ras
oncogene. Importantly, iCCA development in this model
is highly reproducible with 100% of mice developing iCCA
by 14–16 weeks post-hydrodynamic transfection. In addi-
tion, no HCC or mixed HCC/iCCA lesions occur in K-
Ras/NICD mice. Thus, the K-Ras/NICD mouse model is
an ideal preclinical tool to evaluate the therapeutic
potential of drugs targeting the Ras pathway for iCCA
treatment.
Fig. 6 PD901 treatment triggers apoptosis in K-Ras/NICD mouse lesions. a Immunohistochemical staining of pretreated, vehicle-treated, and
PD901-treated K-Ras/NICD mice; b Quantification of CK19(+) area as a measurement of tumor burden in three mouse cohorts. c Proliferation index
and apoptosis index. Scale bars: 200 μm for Myc-tag and CK19 staining; 100 μm in Ki67 staining. Student’s t test, *p < 0.05; **p < 0.01. Pre Pre-
treatment, Veh Vehicle
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The Raf-MEK-ERK cascade has been considered the
major signaling event downstream of K-Ras. Once acti-
vated, it is critical for the regulation of cell growth, sur-
vival, and differentiation. Effects of directly targeting K-
Ras have been largely unsuccessful to date11. In contrast,
targeting signaling molecules downstream of K-Ras has
led to the development of multiple small molecules with
anticancer efficacy. Among all downstream molecules of
K-Ras, the MEK1/2 proteins have a unique structure
allowing the design of ATP-noncompetitive inhibitors
that can lock MEK1/2 into an inactive form. In 1995,
PD98059 was the first reported synthetic small molecule
inhibitor of MEK1/230. Since then, multiple MEK1/2
inhibitors have been developed12,13. PD901 is a highly
selective allosteric MEK1/2 inhibitor with IC50 of 1 nM
against activated MEK1/216. It has been used to study the
therapeutic efficacy of inhibiting MEK proteins in multi-
ple preclinical studies16. PD901 has shown efficacy in
preclinical models of Ras or Raf mutant acute myeloid
leukemia23, colon cancer24, and pancreatic cancer25.
However, its efficacy in iCCA has not been previously
tested. Here, we demonstrate that the treatment of K-Ras/
NICD mice with PD901 leads to stabilized disease mainly
by promoting apoptosis in tumor cells. The results sup-
port the further testing of MEK1/2 inhibitors for the
treatment of K-Ras mutant iCCAs in human patients. It is
important to note that PD901 treatment in K-Ras/NICD
did not lead to a significant decrease in cell proliferation
Fig. 7 Biochemical analysis of PD901-treated K-Ras/NICD mice. a Immunohistochemical staining of p-ERK in pretreated, vehicle-treated, and
PD901-treated K-Ras/NICD mice; b Western blotting analysis of MAPK and AKT pathways in pretreated and PD901-treated K-Ras/NICD mice; c
Western blotting analysis of cell proliferation proteins; d histopathological analysis of PD901-treated K-Ras/NICD livers (upper and middle panel) and
western blot analysis of apoptosis-related proteins (lower panel). Treatment with PD901 resulted in complete tumor necrosis (upper panel; indicated
as N) as well as by infiltration of neoplastic lesions by inflammatory cells (middle panel; arrowhead indicates granulocytes) and induction of apoptosis
(middle panel; apoptotic debris are indicated by arrows)
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(Fig. 6c), which may limit its therapeutic efficacy. Indeed,
we observed that PD901 treatment resulted in stable
disease but not tumor regression in K-Ras/NICD mice.
This finding suggests that PD901 should be combined
with small inhibitors or conventional chemotherapeutic
agents possessing anti-proliferative activity for the treat-
ment of iCCA. In particular, it is worth to note that while
PD901 efficiently inhibited the Ras/MAPK pathway, the
AKT/mTOR cascade remained elevated in K-Ras/NICD
tumor tissues (Fig. 7b). Thus, it is likely that the activated
AKT/mTOR pathway might be one of the driving forces
for the sustained cell proliferation in PD901-treated K-
Ras/NICD lesions as well in human iCCA, and requires to
be further investigated. Therefore, the combination of
PD901 with AKT/mTOR inhibitors might be helpful to
induce growth restraint and tumor regression in K-Ras/
NICD mice and, possibly, human iCCA.
Finally, the data obtained in CCA cell lines unraveled an
anti-growth effect by MEK inhibitors even in K-Ras
wild-type cells, thus suggesting the usefulness of these
drugs in iCCA patients not carrying K-Rasmutation as well.
This finding is important to be mentioned in light of the
almost ubiquitous activation of ERK in iCCA patients that
we have detected in the present study. This evidence is in
accordance with data obtained in other tumor types, where
the MEK/ERK pathway was found to be universally and
robustly activated even in the absence of Ras mutations. In
HCC, for instance, multiple genetic and epigenetic events
disrupting the function of cellular suppressor of Ras, Raf,
MEK, and ERK proteins were identified, resulting in
unrestrained activity of the MEK/ERK cascade in the pre-
sence of wild-type Ras31. Additional investigation to evalu-
ate the frequency and the importance of these alternative
mechanisms of MEK/ERK activation in human iCCA is
Fig. 8 Ubiquitous activation of the MAPK pathway in human intrahepatic cholangiocarcinoma (iCCA) with or without K-Ras mutations.
Immunohistochemical pattern of phosphorylated/activated (p)-ERK1/2, a surrogate marker of MAPK pathway activation, in two human iCCA
specimens, exhibiting mutant K-RasG12D allele (a) and wild-type K-Ras allele (b), respectively. The two iCCA samples are depicted in two
magnifications (x40 and x100) and show strong nuclear immunoreactivity for p-ERK1/2 in the tumor part (T) when compared with non-tumorous
surrounding liver tissues (ST). H&E hematoxylin and eosin staining. Scale bar: 500 μm in x40, 200 μm in x100
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necessary. Furthermore, preclinical models of iCCA exhi-
biting activation of the MAPK pathway in the absence of
K-Ras mutations should be established and subjected to
MEK inhibitors in order to evaluate their relevance in vivo.
Materials and methods
Constructs and reagents
The constructs used for mouse injection, including
Myc-tagged pT3-EF1α-NICD and pCMV/sleeping beauty
transposase (pCMV/SB) plasmids, were described pre-
viously21. pCMV-Cre was obtained from Addgene (plas-
mid #11916). Plasmids were purified using the Endotoxin
Free Maxi Prep Kit (Sigma-Aldrich, St. Louis, MO) before
being injected into the mice. U0126 and PD0325901
(PD901) were purchased from LC Laboratories (Woburn,
MA). Selumetinib and SCH772984 were purchased from
Selleck Chemicals (Houston, TX).
Hydrodynamic tail vein injection and mouse treatment
LSL-K-RasG12D mice in FVB/N background were kindly
provided to us by Dr Allan Balmain of UCSF17. Hydro-
dynamic injections were performed as described pre-
viously32. Briefly, 20 μg of the plasmids encoding pT3-
EF1α-NICD and pCMV-Cre along with sleeping beauty
transposase (pCMV/SB) at a ratio of 25:1 were diluted in
2ml saline (0.9% NaCl) for each mouse. Saline solution
was filtered through a 0.22 μm filter and injected into the
lateral tail vein of 6- to 8-week-old LSL-K-RasG12D mice
within 7 s. PD901 was dissolved in 0.5% (w/v) hydroxy-
propyl-methylcellulose (HPMT; Sigma) in water plus 0.2%
v/v Tween 80 to a stock concentration of 3.33 mg/ml.
PD901 (10mg/kg/day) or vehicle was orally administered
via gavage for 5 days per week. Mice were housed, fed, and
monitored in accord with protocols approved by the
committee for animal research at the University of Cali-
fornia San Francisco (San Francisco, CA).
Histology and immunohistochemistry
Mouse and human liver samples were fixed overnight in
zinc formalin (Anatech Ltd.), embedded in paraffin, cut
into 5-μm-thick sections, and placed on glass slides. Liver
lesions were evaluated by three board-certified patholo-
gists (M.E., K.E., and K.U.). Primary antibodies extensively
validated by the manufacturers for immunohistochem-
istry were selected and listed in Supplemental Table 2.
Briefly, slides were deparaffinized in xylene, rehydrated
through a graded alcohol series and rinsed in PBS. After
boiling in 0.01M citrate buffer (pH 6.0) for 10 min in a
microwave oven, the slides were cooled down at room
temperature, then blocked with 5% goat serum and
Avidin-Biotin Blocking Kit (Vector Laboratories, Burlin-
game, CA). Subsequently, slides were incubated with
primary antibodies overnight at 4 °C. Slides were then
subjected to 3% hydrogen peroxide for 10min to quench
endogenous peroxidase activity and subsequently the
biotin-conjugated secondary antibody was applied at a
1:500 dilution for 30min at room temperature. Finally,
signal was visualized using the Vectastain ABC Elite Kit
(Vector Laboratories In, Burlingame, CA) and developed
with 3,3′-diaminobenzidine. Sections were counterstained
with hematoxylin (Sigma). Negative controls were per-
formed with the same procedure, and PBS was incubated
as a substitute for the primary antibodies.
Assessment of proliferation and apoptosis indices
Proliferation and apoptosis indices were determined in
mouse tumor lesions by counting Ki67 and TUNEL-
positive cells, respectively, on at least 3000 mouse tumor
cells per sample. Indices are expressed as percentage of
positive over total cells counted. TUNEL staining was
conducted using the ApopTag® Peroxidase In Situ
Apoptosis Detection Kit (EMD Millipore, Burlington,
MA), following the manufacturer’s protocol.
Protein extraction and western blotting
Frozen mouse liver specimens and cultured cell samples
were homogenized in Mammalian Protein Extraction
Reagent (Thermo Scientific, Waltham, MA) containing
the Complete Protease Inhibitor Cocktail and sonicated.
Protein concentrations were determined with the Bio-Rad
Protein Assay Kit (Bio-Rad, Hercules, CA) using bovine
serum albumin as standard. Aliquots of 40 μg lysate were
denatured by boiling in Tris-Glycine SDS Sample Buffer
(Invitrogen), separated by SDS-PAGE, and transferred
onto nitrocellulose membranes (Invitrogen, Grand Island,
NY). Membranes were blocked in 5% non-fat dry milk in
Tris-buffered saline containing 0.1% Tween 20 for 1 h and
probed with specific antibodies listed in Supplemental
Table 2. Each primary antibody was followed by incuba-
tion with horseradish peroxidase-secondary antibody
diluted 1:10,000 for 1 h and then revealed with the
SuperSignal West Pico Chemiluminescent Substrate
(Pierce Chemical Co., New York, NY). Equal loading was
assessed by Ponceau Red reversible staining as well as
GAPDH and β-actin western blotting.
In vitro experiments
Human CCA cell lines, including KKU213, HuCCT1,
RBE, KMCH, Huh28, MzCHa1, and OCUG, (Supple-
mental table 4) were used for the in vitro studies. Cell
lines were maintained as monolayer cultures in Dulbec-
co’s modified Eagle medium supplemented with 10% fetal
bovine serum (FBS, Gibco, Grand Island, NY, USA) and
100 U/ml penicillin, 100 g/ml streptomycin (Gibco). For
IC50 determination, cells were seeded in 24-well plates
and treated with increasing doses of U0126 in triplicate
for 48 h. Cells were stained with crystal violet. After
washing, stained cells were treated with lysis solution and
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shaken gently on a rocking shaker for 20–30min. Diluted
lysate solutions were added to 96-well plates and OD was
measured at 590 nm with a BioTek ELx808 Absorbance
Microplate Reader. All cell line experiments were repe-
ated at least three times in triplicate. Cell proliferation and
apoptosis were assessed using the BrdU Cell Proliferation
Assay Kit (Cell Signaling Technology Inc) and the Cell
Death Detection Elisa Plus Kit (Roche Molecular Bio-
chemicals, Indianapolis, IN), respectively, following the
manufacturer's instructions.
Human tissue samples
A collection of formalin-fixed, paraffin-embedded iCCA
(n= 98) samples was used in the present study. The
clinicopathological features of liver cancer patients are
summarized in Supplemental Table 3. iCCA specimens
were collected at the Medical Universities of Greifswald
(Greifswald, Germany) and Sassari (Sassari, Italy). Insti-
tutional Review Board approval was obtained at the local
Ethical Committee of the Medical Universities of Greifs-
wald and Sassari. Informed consent was obtained from all
subjects.
K-Ras sequencing analysis
PCR was performed with 50 ng DNA on the FlexCycler
(Analytik Jena, Jena, Germany) thermal cycler. Briefly, the
reaction was carried out using the innuTaq HOT-A DNA
Polymerase with 10× PCR buffer with KCl (Analytik
Jena), in a total volume of 25 µl, containing 0.2 µm of each
primer, 200 µm of each dNTP, 1.5 mM MgCl2, and 0.5 U
DNA polymerase. An initial denaturation for 3 min at 94 °
C was followed by 40 cycles of 94 °C for 45 s, 65 °C for 45
s, and 72 °C for 45 s, with a final elongation step of 10 min
for 72 °C. Primers were obtained from Biomers (Ulm,
Germany) and sequences were taken from the literature28.
Sequencing was performed with the GenomeLab DTCS
Quick Start Kit (Beckman Coulter, Pasadena, CA) on the
GenomeLab GeXP (Beckman Coulter).
Statistical analysis
Data analysis was performed with Prism 6 (GraphPad,
San Diego, CA). All data are presented as Means ±SD.
Comparisons were performed with Student’s two-tailed
unpaired t test or Tukey Kramer test. P values <0.05 were
considered statistically significant.
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